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Abstract: The coexistence of depression and cardiovascular disease (CVD) is regularly   
discussed, and much debated. There is strong evidence that there are pathophysiological mecha-
nisms, particularly endothelial dysfunction, altered platelet aggregation, and hyperactivation 
of the thrombosis cascade, which coexist with hypothalamic-pituitary-adrenocortical axis 
dysfunction, and link depression to CVD. Therefore, depression should not be automatically 
considered to be a consequence of life impairment due to myocardial infarction or major stroke. 
Probably, it should be considered as one of the many other stressful events, or “genetic reactions 
to life”, which are risk factors for CVD development. This review will examine the significance 
of depression in clinical daily practice, its pathophysiology as a determinant in vascular events, 
and its real importance in, before, and after many CVD events.
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Introduction
Depression is a major condition in the 21st century. Clinicians should consider   quality 
of life, pain, anxiety, loss of sense of humor, depression, and apathy as clinical condi-
tions which have an impact on every specialist field. When dealing with older persons, 
especially those with chronic disease conditions and comorbidities, depression is an 
everyday problem for the neurologist and the internal medicine specialist. Behavioral 
disturbances may have a contribution to the overall morbidity of every disease, espe-
cially in elderly patients, and depression may lead to institutionalization,1,2 mainly 
due to consequent inadequate nutrition, altered sleep, and problems in adhering to 
prescription medicine regimes.
There is a well-known relationship between cardiovascular disease (CVD) and 
depressive disorders.3–6 The connection is unclear: studies have focused on etiopatho-
genesis, consequences of inadequate or non-target therapies, and the socio-economic 
impact of under-diagnosis. However, the effects of antidepressive therapy on CVD 
overall mortality seem to be limited7,8 and the analysis of a causal link with cardiovas-
cular drugs has generated conflicting results. The debate is whether altered behavior 
is generated by CVD, or conversely, whether it precedes CVD.9 Compared with 
  euthymics, depressed patients are significantly less likely to adhere to prescribed 
medications, follow lifestyle recommendations, practice self-management, and even 
attend follow-up cardiac testing. Hence, depression itself may not necessarily be a direct 
cause of adverse outcome but may serve as a barrier to the delivery of optimal care.
A further possibility is that depression is a secondary event in cardiac patients. 
In this view, the adverse outcome is the result of the greater disease burden, not of Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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depression per se. Several factors go against this explanation. 
Many studies6,10,11 have used risk adjustment for cardiac and 
non-cardiac disease burden in their analyses, and adjustment 
for these variables does not appear to rule out the relationship, 
supporting the conclusion that depression is an independent 
predictor of CV outcome. Moreover, depression precedes 
cardiovascular disease in community studies, being predic-
tive of first myocardial infarction (MI) and cardiac death in 
healthy individuals.9,10
Antidepressants may well increase the survival of the 
cardiovascular patient, as shown in a preliminary study 
on post-stroke depression,8 although some data reported 
the persistence of endothelial dysfunction even in treated 
depression,12 giving a scientifically plausible explanation of 
the limited result of the Enhancing Recovery in Coronary 
Heart Disease Patients Randomized (ENRICHD) trial.7 
Mood may be influenced by health and the pharmacological 
consequences of a cardiovascular event, so that individuals 
with more severe disease are more likely to suffer from 
depressive symptoms.
Epidemiology
Recently, many studies4,10,14 have demonstrated that depres-
sive symptoms are a strong predictor of CVD mortality, as are 
previous MI, diabetes, and cardiac ejection fraction. These 
studies, however, do not clarify the nature of the relation-
ship between depression and cardiac disease. Depression not 
only has known neuroendocrine effects that could influence 
stroke risk, but also may negatively impact on other stroke 
risk factors.
Several studies have analyzed and supported this 
association.14–16 The best epidemiological evidence for a sig-
nificant positive relationship between depressive symptoms 
and stroke mortality has been provided by Everson et al.16 In 
a 29-year follow-up, they evaluated the association between 
depressive symptoms and stroke mortality in a community 
sample of 6676 stroke-free men. After adjustment for estab-
lished stroke risk factors, individuals reporting 5 or more symp-
toms of depression at baseline experienced more than a 50% 
excess risk of mortality due to stroke during the subsequent 29 
years, providing compelling evidence that depressive symp-
toms are significant factors in subsequent stroke mortality.
Another fundamental step in the comprehension of the 
stroke-depression link comes from the results of Multiple 
Risk Factor Intervention Trial (MRFIT).17 Stroke turns out to 
be the specific CVD cause with which depressive symptoms 
are associated. Its clinical significance lies in the fact that 
the risk of stroke in severely depressed patients was twice 
as high as in nondepressed subjects. However, this study has 
some limitations. Firstly, the findings are restricted to men at 
a high risk of CVD and the strength of the depression-stroke 
association may be typical of populations with a high preva-
lence of hypertension. Secondly, the assessment of depressive 
state occurred towards the end of MRFIT and by this time 
22% of participants were no longer free of CVD.
It is important to bear in mind that there are also studies 
that did not confirm the previous association.18,19
O’Donnell et al20 have studied the contribution of known 
and emerging risk factors to stroke and its primary subtypes, 
assessed the contribution of these risk factors to the burden 
of stroke, and explored the differences between risk fac-
tors for stroke and myocardial infarction. They undertook a 
standardized case–control study in 22 countries worldwide 
between March 1, 2007, and April 23, 2010. Cases were 
patients with acute first stroke (within 5 days of onset of 
symptoms and 72 hours of hospital admission). Controls 
had no history of stroke, and were matched with cases for 
age and sex. The authors calculated odds ratios (ORs) and 
population-  attributable risks (PARs) for the association of all 
strokes, ischemic stroke, and intracerebral hemorrhagic stroke 
with selected risk factors. In the first 3000 cases (n = 2337, 
78%, with ischemic stroke; n = 663, 22%, with intracerebral 
  hemorrhagic stroke) and 3000 controls, significant risk factors 
for all strokes were: history of hypertension; current smoking; 
waist-to-hip ratio; diet risk score; regular physical activity; 
diabetes mellitus; alcohol intake, which is normally regarded 
in general clinical practice as being related to anxiety and 
mood alteration (OR: 1.51, 95% CI: 1.18–1.92 for more than 
30 drinks per month or binge drinking; OR: 3.8%, 95% CI: 
0.9–14.4); psychosocial stress (OR: 1.30, 95% CI: 1.06–1.60; 
OR: 4.6%, 95% CI: 2.1–9.6) and depression (OR: 1.35, 95% 
CI: 1.10–1.66; OR: 5.2%, 95% CI: 2.7–9.8); cardiac causes; 
and ratio of apolipoproteins B to A1.   Collectively, these risk 
factors accounted for 88.1% (99% CI: 82.3–92.2) of the 
PAR for all strokes. These risk factors were all significant for 
ischemic stroke, whereas hypertension, smoking, waist-to-hip 
ratio, diet, and alcohol intake were significant risk factors for 
intracerebral hemorrhagic stroke. The fact that these ten risk 
factors are associated with 90% of the risk of stroke provided 
evidence that altered mood, depression, anxiety, binge drink-
ing and psychosocial stress are linked to CVD.
Paranthaman et al21 tried to explain vascular function in 
depression. Their study assessed endothelial function, arterial 
stiffness, and atherosclerosis in a variety of vessel beds in 
25 elderly subjects with depressive disorder, compared with 
21 nondepressed control subjects. Subjects underwent pulse Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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wave velocity, pulse wave analysis, carotid intima/media 
thickness analysis, and magnetic resonance imaging. A   subset 
(16 patients and 15 control subjects) had assessment of biop-
sied small artery dilatation to   acetylcholine to further assess 
endothelial function. The mean sample age was 72.4 years 
with an average age at onset of depression of 60 years. Mean 
carotid intima media thickness was significantly higher in 
depressed subjects (P , 0.01). Pulse wave velocity was 
1.6 m/s higher in depressed subjects (borderline significance). 
There was a significant reduction in the dilatation response 
to acetylcholine in preconstricted small arteries (P = 0.01). 
On magnetic resonance imaging, depressed subjects had 
significantly more dilated Virchow-Robin spaces in the basal 
ganglia (P = 0.01). Depressed subjects had a greater volume 
of white matter lesions in all regions, but this did not reach 
statistical significance. There were no baseline   differences in 
vascular risk. Paranthaman et al21 concluded that depression in 
the elderly is associated with poorer endothelial function and 
more atherosclerosis. This is associated with a greater white 
matter lesion load and basal ganglia microangiopathy.
Few studies have examined the relationship between cere-
brovascular changes, depression, and long-term prognosis. 
Yamashita et al22 examined the effects of cerebrovascular 
changes on the course of geriatric depressive symptoms, 
dementia rates, and mortality over a follow-up period of 
approximately 10 years. Eighty-four patients with major 
depression (age of onset over 50 years) were enrolled in this 
study; patients suffering from strokes, neurological disorders, 
and other psychiatric disorders were excluded. Magnetic 
resonance imaging findings were used to classify all patients 
into silent cerebral infarction (SCI)-positive (n = 37) or SCI-
negative groups (n = 47). Prognoses were ascertained using a 
review of clinical charts and mailed questionnaires. Yamashita 
et al22 pointed out that only 5% of patients with SCI main-
tained remission whereas 36% of patients   without SCI did so. 
Total duration of depressive episodes was   significantly longer 
in the SCI-positive group than in the SCI-negative group. 
SCI was also associated with a higher risk of dementia. The 
results of this long-term follow-up study demonstrate that the 
presence of SCI is associated with a relatively poor prognosis 
in geriatric depression.22
These data have been confirmed by other recently 
published studies. Wouts et al23 examined the interaction 
between vascular disease and neuroticism as determinants 
of clinically relevant depressive symptoms in late-life: the 
study involved a multivariate logistic regression on data from 
a survey of 1396 people aged $70 years. Clinically relevant 
  depressive symptoms (CRDS) were defined as high scores 
in the   appropriate scale, in particular by the 20-item Epide-
miological Studies Depression Scale (CESD) and defined as 
a score of $16. Vascular disease was   categorized into four 
levels: none, $2 vascular risk factors, cardiac disease or 
stroke. Neuroticism was strongly associated with CRDS in 
women (OR: 1.6, 95% CI: 1.4–1.8). In men, vascular   disease 
interacted negatively but significantly with   neuroticism (car-
diac disease by neuroticism: OR: 0.8, 95% CI: 0.6–0.9; stroke 
by neuroticism: OR: 0.8, 95% CI: 0.6–0.96) when   predicting 
CRDS. These authors suggested that in men,   vascular disease 
attenuates the predictive value of   neuroticism in CRDS, 
which might be mediated by apathy caused by cerebrovas-
cular disease.
Apathy, one major determinant of geriatric depression, 
has been considered a major determinant of poorer outcomes 
in various clinical conditions;24,25 very recently, Jorge et al26 
reviewed the available evidence on the frequency, clinical 
correlates, mechanism, and treatment of apathy following 
stroke. The frequency of apathy following stroke has been 
consistently estimated at between 20% and 25%. Jorge et al26 
found that apathy appears to be associated with the presence 
of cognitive impairment, a chronic course characterized by 
progressive functional decline, and with disruption of neural 
networks connecting the anterior cingulate gyrus, the dorso-
medial frontal cortex, and the frontal pole with the ventral 
aspects of the caudate nucleus, the anterior and ventral globus 
pallidus, and the dorsomedian and intralaminar thalamic 
nuclei. Apathy is a frequent neuropsychiatric complication 
of stroke that, although often associated with depression and 
cognitive impairment, may occur independently of both. 
Its presence has been consistently associated with greater 
functional decline. However, there is no conclusive evidence 
about what is the best treatment for this condition.
There is a newly emerged concept of “vascular 
depression”.27–29 The depression-executive dysfunction 
  syndrome has been conceptualized as an entity with 
  pronounced frontostriatal-limbic dysfunction. Clinically, it is 
characterized by reduced interest in activities, psychomotor 
retardation, impaired function in daily living,   suspiciousness, 
impaired insight, and limited vegetative signs.30 This 
  syndrome has also been shown to have a poor, slow and 
unstable response to antidepressant medications27–30 and may 
respond better to problem-solving therapy.31
These observations formed the basis of the vascular 
depression hypothesis, according to which cerebrovas-
cular disease may predispose, precipitate, or perpetuate 
some geriatric depressive syndromes.32,33 Elderly patients 
with vascular depression have more apathy, retardation, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and lack of insight and less agitation and guilt than those 
with   nonvascular depression.32,34 Verbal fluency and nam-
ing are the most impaired cognitive functions in vascular 
  depression. Finally, patients with this form of depression 
have greater disability compared to those who are depressed 
but have no vascular impairment.34 The vascular depression 
hypothesis has led to hypotheses with clinical ramifications. 
  Ameliorating cerebrovascular risk factors (eg, hypertension 
or hypercholesterolemia) or employing agents promoting 
vascular integrity (eg, antiplatelet agents, calcium channel 
blockers, or antioxidants) might reduce the risk of vascular 
depression. A study using the calcium channel blocker nimo-
dipine as an augmenting agent led to improved antidepressant 
treatment outcomes compared to antidepressant monotherapy 
among patients with vascular depression.35 Furthermore, the 
choice of antidepressant treatment may be guided by the 
presumptive knowledge of the underlying vascular etiology. 
Catecholaminergic enhancing agents   promote better func-
tional recovery from ischemic brain lesions in comparison 
with serotoninergic agents or antidepressants with alpha 
blocking action.33
Depression and predisposing  
factors for CVD
Depression is associated with several physiological derange-
ments that could contribute to adverse cardiac outcomes, 
such as high sympathetic tone, hypercortisolemia, elevated 
catecholamine levels, abnormal platelet activation and 
endothelial dysfunction. However, these physiological 
abnormalities, constantly present in depressed patients, do 
not always produce CVD.3,12,36
In particular, depressive disorder might be characterized 
by the presence of an abnormal feedback loop involving the 
prefrontal cortex, the amygdala, hypothalamic-pituitary axis37 
and noradrenergic brainstem nuclei.2,24 The medical conse-
quence of these alterations is widespread, including coagula-
tion alterations, endothelial injury38 and hypertension.39
Depression is evoked as a major determinant in the 
alteration of various basic systems involved in homeostasis. 
First of all, mental stress and depression seem to be involved 
in endothelial alteration. Healthy endothelium maintains 
vascular tone via nitric oxide (NO) metabolites, inhibits 
smooth-muscle cell proliferation, and inhibits the adhesion 
of leukocytes and platelet adhesion/aggregation. In humans, 
several risk factors for CVD (including smoking, diabetes, 
and hypertension) have been shown to induce endothelial 
dysfunction from an early stage, with alterations in the 
NO system. Rajagopalan et al38 and Broadely et al12 have 
shown that flow-mediated dilatation (FMD) is impaired both 
in untreated and treated depression, suggesting a possible 
contribution to the increased CVD risk seen in depression. 
On the other hand, a more recent study, using a selective 
serotonin reuptake inhibitor (SSRI) as antidepressant therapy, 
showed endothelium-protective properties associated with 
the use of sertraline.40 More recently, Chrapko et al41 have 
shown that platelet NOS activity and plasma levels of NO 
metabolites were dramatically lower in patients with major 
depression, compared to healthy controls.41 The decreased 
NO production is particularly relevant in depressive patients 
with cardiovascular risk and might contribute to the observed 
increased platelet reactivity found in these patents.42
Along with endothelium integrity, platelets are the co-
protagonists of the scenario called “atherothrombosis”, 
which remains the leading cause of cardiovascular deaths. 
Under physiological conditions, platelets’ relationship with 
damaged vessels determines the arrest of platelets, followed 
by spreading aggregation. This is mainly caused by the acti-
vation of Gp IIb-IIIa.43 This interaction triggers   platelet’s 
procoagulant activities,44 via the 5-hydroxytryptamine 
(5-HT) pathway. 5-HT receptors are widely involved in 
several recognized functions, including attention, percep-
tion, pain sensation, mood, and anxiety. Therefore, many 
authors have linked the alteration of central serotoninergic 
pathways (typical of depression and dysthymia) and athero-
sclerotic process of CVD.7 Laghrissi-Thode et al46 showed 
that depressed patients with ischemic heart disease showed 
elevated β-thromboglobulin levels, increased plasma levels 
of platelet factor 4, and increased surface receptor expres-
sion of Gp IIb-IIIa and P-selectin, when compared with 
nondepressed ones.
Musselman et al42 evaluated the response of platelets (in 
vivo activation, secretion and dose response   aggregation) 
to antidepressant treatment. In vivo platelet activation, 
secretion, and dose-response aggregation in the controls 
and patients was measured after overnight bedrest under 
basal conditions, and after a mild exercise challenge. After 
6 weeks of open-label treatment with the SSRI paroxetine 
(20 mg/day), the patients with depression were readmitted 
and tests were repeated. Compared with matched controls 
(12 subjects without CVD risk factors), the depressed group 
exhibited, at baseline, a 125% increase in binding of the 
monoclonal antibody anti ligand-induced binding site (mAb 
anti-LIBS anti-GPIIIa), a 50% increase of mAb anti-GA6 
binding (anti-P-selectin), and a 150% plasma concentra-
tion increase in the platelet-specific secretion protein PF4. 
After paroxetine treatment, the patients with depression Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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exhibited significant reductions in all three parameters. After 
6 weeks of paroxetine treatment, 12 (80%) out of 15 patients 
were good responders, and exhibited a 48% decrease in 
m-Ab anti-LIBS binding, a 17% decrease in mAb GA6 
binding and a 54% decrease in PF4 plasma level; measures 
not significantly different from the baseline values of the 
controls. Normalization of platelet activation is associated 
with paroxetine treatment of patients with depression. 
Because this study design did not allow for the determination 
of whether this effect of paroxetine on platelet function is a 
direct effect of the drug or a placebo effect, or, alternatively, 
because of recovery from depression, studies containing a 
placebo and/or psychotherapy treatment arm may be needed 
to resolve this issue. Interestingly, the increased anti-LIBS 
platelet binding of depressed patients was observed not 
only in subjects with conventional CVD risk factors, but 
also in ones without, suggesting that increased anti-LIBS 
platelet binding is not a surrogate marker for conventionally 
accepted CVD risk factors.42
These findings, together with results from the Sertraline 
Antidepressant Heart Attack Randomized Trial (SADHART) 
substudy,40 confirm the central role of platelets in the genesis 
of both depressive and cardiovascular disorders and suggest 
that SSRIs not only may diminish CVD risk among depressed 
subjects, but also could be a safe and a useful tool for   secondary 
CVD prevention in cardiopathic depressed patients.
Finally,  there  is  an  increased  activation  of  the 
  hypothalamic-pituitary-adrenal (HPA) axis in major depres-
sion, resulting in a high cortisol level and sympathetic 
tone. Considering that depression has been associated with 
increased cortisol in ischemic heart disease (IHD) patients36 
and that hypercortisolism is well known to redistribute 
body fat, promote the development of atherosclerosis, and 
  accelerate injury to endothelial cells, cortisol may act as 
a mediator between depression and cardiovascular events. 
Cortisol induces a downregulation of endothelial nitric 
oxide synthetase (eNOS), as well as a decrease in plasma 
NO levels.39   Cortisol therefore may increase cardiovascular 
risk in depressed patients inducing endothelial dysfunc-
tion. More recently, Wilbert-Lampen et al37 have suggested 
that corticotropin-releasing hormone (CRH) induces a 
significant increase of cell adhesion as well as monocytic 
MAC-1 expression and increases monocytic ET-1 release, 
diminishing NO release. All these effects have been abol-
ished by the CRH-antagonist “astressin”. These data sup-
port the hypothesis that, in depression, cortisol increases 
cardiovascular risk via endothelial dysfunction, providing 
also a novel concept of how specific CRH-antagonists may 
prevent CRH (stress)-related endothelial dysfunction lead-
ing to cardiovascular complications. Stress has been shown 
to be one of the most powerful inducers of depression,46 via 
the HPA axis. Once stress has been resolved, normally all 
the underlying biochemical and   hormonal alterations should 
return to their base states.   However, genetic predisposition, 
such as specific 5-HT transporter gene polymorphisms, 
coupled with gene–environment interaction, may explain 
why some subjects recover from life stress factors while 
others develop depression, anxiety, somatic pain and so on.47 
Genetic association studies in geriatric depression have impli-
cated the serotonin pathway, especially in men. In elderly 
twin studies, both the serotonin 2A receptor gene promoter 
A/A genotype and a specific haplotype in VMAT2, the gene 
encoding the   vesicular monoamine transporter, were associ-
ated with depression symptoms in men, but not in women.48,49 
The serotonin transporter gene has been implicated in the 
emergence of depression following medical stress or psycho-
social adversity. In young adults, the presence of a specific 
allele (s allele)   predicted increased rates of major depressive 
disorder, depressive symptoms, and   suicidal ideation after 
various life stressors (eg, medical insults, psychosocial, or 
financial hardships).47 This is consistent with the finding of 
increased rates of major depressive disorder and depressive 
symptoms among elderly patients who suffered a hip fracture 
and carried at least one s allele of the serotonin transporter 
gene-linked polymorphic region (5-HTTLPR), compared 
to elderly patients who also suffered a hip fracture but car-
ried no s alleles.47 The s allele, as opposed to the l allele of 
5-HTTLPR, was also found to be associated with slower 
speed of response and more   pronounced side effects in phar-
macogenetic studies of elderly depressives.50,51
The BDNF-gene Val66Met polymorphism is more 
  frequent among elderly depressed patients than among 
controls52 and seems, along with the s allele of 5-HTTLPR, 
to increase the risk of depression following various environ-
mental stressors.53
Patients with late-onset major depression carried the 
C677T mutation of the enzyme methylene   tetrahydrofolate 
reductase (MTHFR) more frequently than controls.54   Cerebral 
autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy, a condition characterized by 
recurrent subcortical strokes and frequently presenting with 
depression, is caused by mutations in the notch3 gene.55 
The ε4 allele of apolipoprotein-E increases the risk for two 
conditions associated with geriatric depression, Alzheimer’s 
disease56 and cerebrovascular disease,57 but in a community 
sample it was not associated with late-life depression.58Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The stress-induced hypothesis suggests that depression 
could be a direct risk factor for both the development of 
cardiovascular disease and increased CVD morbidity and 
mortality for patients with preexisting disease; conversely, 
a genetic pathway which renders a patient a “good stress 
responder”, should protect the subject from CVD complica-
tion after prolonged stress factors.
Cardiovascular side-effects  
of antidepressant drugs
Given that depression might potentiate CVD, coexist with it, 
or eventually predispose to its development, clinicians should 
treat it, while taking into account that many antidepressant 
drugs have cardiovascular side effects. In recent years, with 
the introduction of new antidepressants, the number of treat-
ment options, as well as the safety of these treatments, has 
increased.59
It is known that tricyclic antidepressants (TCAs) currently 
available are associated with anticholinergic and cardiotoxic 
side effects. In addition, research into the possible role of 
oxidative stress in TCA-induced cardiotoxicity has found 
that free radical generation and oxidative stress play a role 
in clomipramine-induced cardiotoxicity.60 TCAs may induce 
sinus tachycardia in many patients and orthostatic hypoten-
sion occurs in up to 20% of patients receiving TCAs. Postural 
hypotension is responsible for a number of injuries in the 
elderly. For this reason, it is necessary to suspend treatment 
in 25%–50% of patients with pre-existing cardiovascular 
disorders.61 The TCA compound with minimal orthostatic 
hypotensive properties is nortriptyline. Therefore, when other 
antidepressant treatments have been ineffective, nortriptyline 
is considered to be the TCA of choice for treatment of depres-
sion in patients suffering from cardiovascular disorders, and 
the elderly.59
TCAs concentrate in the myocardium leading to   significant 
changes in conduction and myocardial contractility. Indeed, 
TCAs may cause first and second-degree atrioventricular 
block, asystole and sudden cardiac death.62 Additional stud-
ies have suggested that for low doses of TCAs (less than 
100 mg/day amitriptyline or its equivalent), there is no evi-
dence of increased risk of sudden cardiac death.63,64 However, 
since higher doses of TCAs are found to increase relative risk, 
such doses should be used cautiously, particularly in patients 
with preexisting cardiovascular disease.63 During TCA treat-
ment, asymptomatic ECG modifications (ie, lengthening of 
the QT, PR and QRS intervals) have been observed. These 
alterations are generally clinically   insignificant in healthy 
subjects, but in patients with   pre-existing conduction disorders 
(in particular bundle branch block) they may cause serious 
conduction disorders in approximately 20% of cases. There 
is evidence that these effects are due to the anti-arrhythmic 
properties of these drugs which resemble those of class I anti-
arrhythmics (including quinidine, procainamide, disopyra-
mide, encainide,   flecainide, propafenone and moricizine). This 
quinidine-like action is highly potent for imipramine.64 The 
effects of TCAs have been investigated in patients who experi-
ence frequent premature ventricular contractions (PVCs). In 
this connection, TCAs have been reported to be effective in 
  decreasing the frequency of PVCs in non-depressed patients 
with cardiac disorder.64,65 However, although patients who 
suffer from frequent PVCs after a myocardial infarction show 
a higher mortality rate than those with fewer PVCs, it would 
appear that TCAs lower the frequency of PVCs at the cost of 
  further decreasing long-term survival.66 In conclusion, TCAs 
must be considered unsafe in patients with cardiovascular 
disorders.
Today,  given  the  dietary  and  drug  restrictions, 
  non-selective and irreversible monoamine oxidase inhibitors 
(MAOIs) have been virtually abandoned by clinicians for the 
treatment of depression. Moclobemide, which appears to be 
the only MAOI actually employed, does not appear to alter 
cardiac conduction or QT interval. Isolated cases of marginal 
decrease in the heart rate have been reported.67 Therefore, 
caution is recommended in the treatment of patients with 
cardiovascular disease.
Selective serotonin reuptake inhibitors (SSRIs) are 
  generally considered safer than TCAs in patients with cardiac 
disorder. In fact, SSRIs are devoid of antimuscarinic proper-
ties, and do not induce postural hypotension, tachycardia, or 
alterations in the PR or QRS intervals. Unlike TCAs, SSRIs 
do not have anti-arrhythmic effects.59
A number of specific studies aimed at assessing the safety 
of SSRIs in patients with depression and cardiovascular dis-
order were conducted. In particular, an open 7-week study 
was conducted on patients with DSM-III-R criteria for major 
depression, Hamilton Rating Scale for Depression (HAM-D) 
score $ 16, with a variety of cardiac states. The cardio-
vascular effects of fluoxetine at a dose of up 60 mg/kg day 
(n = 27) were compared with those (n = 60) of nortriptyline 
(1 mg/kg of body weight and titrated to a therapeutic plasma 
level of 50–150 ng/mL). Fluoxetine did not exhibit the 
cardiovascular side-effects seen with nortriptyline (such as 
orthostatic hypotension, cardiac conduction abnormalities 
or tachycardia).68
A double-blind randomized placebo-controlled trial 
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  cardiovascular responses to treatment with sertraline in 
369 depressed patients with either acute MI or unstable 
angina. At the end of 24 weeks of treatment, sertraline (mean 
dose 68.8 ± 40.1 mg/day) was found to be safe and effective 
in these patients.69
A case control study of 5236 patients demonstrated 
a significant reduction in risk of MI associated with cur-
rent use of high affinity SSRIs (sertraline and paroxetine) 
  compared with both non-use of antidepressants and use of 
other antidepressants. In addition, the extent of 5-HT inhi-
bition among SSRIs correlated with the degree of reduced 
odds of MI. These results suggest that the relative reduction 
in platelet 5-HT uptake caused by SSRIs is the reason for 
the risk reduction.70
Probably the most important side-effect of SSRIs in 
patients with cardiovascular comorbidity is their potential 
to interact with drugs these patients are taking for cardiac 
arrhythmias, congestive heart failure or hypertension.
The SSRIs paroxetine and fluoxetine are potent 
CYP2D6 inhibitors, whereas citalopram, fluvoxamine and 
sertraline are weak inhibitors. Also, escitalopram, the active 
S-enantiomer of citalopram is a weak inhibitor of CYP2D6.43 
With respect to CYP3A4, all SSRIs are weak inhibitors 
(fluvoxamine moderate). Therefore, SSRIs can increase 
plasma concentrations of cardiovascular drugs metabolized 
by CYP2D6, such as propranolol, metoprolol, flecainide, and 
encainide, or metabolized by CYP3A4, such as simvastatin, 
lovastatin, amlodipine, nicardipine, nifedipine, diltiazem 
and amiodarone.71
Attention should also be paid to the interaction between 
SSRIs and other serotoninergic drugs (ie, clomipramine, 
lithium, MAOIs, moclobemide, selegiline, SSRIs, tramadol, 
L-tryptophan, meperidine, dextromethorphan) in view of the 
occurrence of the 5-HT syndrome.72
There is also emerging insight into the importance of 
the interaction between SSRIs and thiazide diuretics. The 
careful monitoring of patients prescribed both an SSRI and 
a thiazide diuretic is suggested, since severe hyponatremia 
may occur through inappropriate ADH release.73
In conclusion, SSRIs are considered first choice drugs for 
treatment of patients with cardiovascular disorders. Patients 
who have experienced a myocardial infarction may be treated 
either with fluoxetine or sertraline. Sertraline, however, may 
be preferable, due to its better side-effect profile. Patients 
with ischemic heart disease who have not had a myocardial 
infarction may be treated either with paroxetine or sertraline. 
Patients with heart failure may be treated with fluoxetine 
or sertraline. Again, sertraline may be preferred in these 
patients given its lack of effect on left ventricular ejection 
function.74
Cardiovascular tolerability of any serotonin noradrenaline 
reuptake inhibitors (SNRIs) varies within the class, venla-
faxine seeming to be the least well-tolerated, principally due 
to dose-dependent hypertension.
A meta-analysis of original data on blood pressure of 
3774 patients indicated that venlafaxine treatment caused 
dose-dependent increase in supine diastolic blood pressure, 
but clinically significant hypertension is only induced at 
doses . 200 mg/day.75
Blood pressure increases with milnacipran are minimal. 
A review of over 4000 patients treated with milnacipran 
reported that the mean increase in blood pressure was 
1 mmHg while the mean increase in heart rate was 3.6 bpm. 
However, milnacipran can, at high doses, cause tachycardia 
and hypertension in certain patients.76
With respect to duloxetine, a recent meta-analysis of 
  cardiovascular safety indicated small but significant increases 
in heart rate and systolic blood pressure, compared with 
  placebo, but these were similar to the effects seen with 
fluoxetine and paroxetine. Mean changes in ECG were 
  neither clinically nor statistically significant.77 In conclu-
sion, milnacipran and duloxetine appear better tolerated than 
venlafaxine, and are essentially devoid of cardiovascular 
toxicity.78
Evidence has accumulated for the role of noradrena-
line serotonin specific antidepressants (NASSAs), such as 
  mirtazapine in the treatment of patients with depression and 
cardiac disease.
In a double-blind study, 50 healthy subjects were 
  randomized to receive either mirtazapine (up to blind 
30 mg/day) or placebo for a 4-week period. Mirtazapine 
subjects showed significantly increased total cholesterol 
(TC) at week 4, but no significant changes in HDL, LDL 
levels and TC/HDL ratios.79 Isolated cases of hypertensive 
episodes and tachycardia have been reported during treatment 
with mirtazapine.80 In conclusion, mirtazapine would seem 
relatively safe in patients with cardiac disorders.
Noradrenaline selective reuptake inhibitors (NARIs) 
such as reboxetine are thought to be problematic in patients 
with heart disease. However, a single-blind study compared 
the acute and long-term effects of reboxetine (2 mg twice a 
day) administered to twelve depressed patients with those of 
  placebo; long-term treatment with reboxetine did not cause 
any significant change in cardiac autonomic function.81 
A   double-blind placebo controlled study evaluated the efficacy 
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Table 1 A synopsis of cardiovascular disease (CVD) side effects of antidepressants
Class of agents Specific effects General effects Not CVD patients CVD patients
Tricyclic antidepressants  
(TCA)
Free radical  
generation;  
oxidative stress
(clomipramine) 
The quinidine-like  
action is highly  
potent for  
imipramine
Sinus tachycardia
Orthostatic  
hypotension (20%)
Significant changes in  
conduction and myocardial  
contractility (first and  
second degree  
atrioventricular block)
Quinidine-like action
Premature ventricular  
contractions
Asystole
Lengthening QT,  
PR and QRS intervals
Sudden death
Caution in  
hypotensive  
patients
Caution in patients  
with pre-existing  
cardiovascular disease;  
caution in patients with  
pre-existing conduction  
disorders (bundle  
branch block); caution  
in CVD
Monoamine oxidase  
inhibitors (MAO-is)
interactions with  
tyramine;
interactions with  
methyl-dopa; 
reserpine and  
guanethidine,  
employed (even if  
rarely as anti- 
hypertensive drugs)
isolated cases of marginal  
decrease in heart rate
No recommendation Virtually abandoned;  
caution in CVD
Selective serotonin  
reuptake inhibitors (SSRi)
SSRis can increase  
plasma concentrations  
of cardiovascular drugs  
metabolized by  
CYP2D6, such as  
propranolol,  
metoprolol, flecainide  
and encainide or  
metabolized by  
CYP3A4, such as  
simvastatin, lovastatin,  
amlodipine,  
nicardipine, nifedipine,  
diltiazem and  
amiodarone
Hyponatremia (and therefore  
major attention to thiazide  
and SSRi interactions)
No specific  
recommendation
Caution in patients with  
acute left ventricular  
altered functions
First choice drugs for  
the treatment of patients  
with CVD
Serotonin noradrenaline  
reuptake inhibitors (SNRi)
Dose-dependent hypertension
Dose dependent increase in  
supine diastolic blood pressure
Small but significant increase  
in heart rate
No recommendation No recommendation
Noradrenaline serotonin  
specific antidepressants  
(NASSA)
Single cases  
of reported
hypertension  
Tachycardia
Significant increase levels  
of total cholesterol
No recommendation No recommendation
Noradrenaline-selective  
reuptake inhibitors (NARi)
Hypertension No serious  
event in patients  
without CVD
No recommendation  
in patients with CVD
Serotonin-antagonists/ 
reuptake inhibitors (SARi)
Arrhythmias 
Minor effects on systolic  
time intervals;
Asymptomatic bradycardia 
hypotension
No serious  
event in patients  
without CVD
warning in CVD patients
Dopamine/noradrenaline  
reuptake inhibitors
Significant rise in supine systolic  
and diastolic blood pressure
No serious event in  
patients without CVD
Not extensively studied in   
CVD patients; warning in  
pre-existing hypertensionVascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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a subset of post-stroke depressed patients (PSD) (classified as 
affected by “retarded depression”). Results showed the safety 
and good tolerability of this antidepressant that may be a   useful 
option in PSD patients not responsive to SSRIs.82
In the category of serotonin-antagonists/reuptake inhibi-
tors (SARIs), trazodone appears to have no anticholinergic 
or quinidine-like properties in comparison with amitriptyline 
in depressed patients with cardiac abnormalities, although 
it can induce minor effects on systolic time intervals.83 Case 
reports of arrhythmias have been described.84 Because of 
its cardiac side effects, trazodone is less desirable for use 
in cardiac patients. Trazodone prolonged-release may be a 
therapeutic option in the treatment of patients with major 
depression with major sleep disturbances,85 but its cardiac 
properties should be taken into account.
Nefazodone, related chemically to trazodone, has 
also noradrenaline reuptake-inhibiting properties.86 
  Cardiovascular safety evaluations conducted on the ECGs 
of 1,153 patients receiving nefazodone in placebo-controlled 
trials showed no significant differences between the treat-
ments. An asymptomatic sinus bradycardia occurred in 1.3% 
of placebo patients (P # 0.05). There was no evidence that 
nefazodone can alter cardiac conduction or rhythm.87 Nefa-
zodone may be   considered relatively safe in patients with 
depression and heart disease. Caution is required in patients 
with recent MI.
Dopamine/noradrenaline reuptake inhibitors such as 
bupropion seem not to be as cardiotoxic as TCAs but have 
not been studied extensively in patients with cardiac disease. 
A prospective observational trial conducted for 3 weeks 
evaluated 36 patients suffering from major depression 
(DSM criteria) and a variety of cardiac diseases. Patients were 
given bupropion 150 mg/day (starting dose) up to 450 mg/day 
(by day 7). Results showed no significant changes in left 
ventricular function or PR and QRS intervals. Bupropion did, 
however, cause a significant rise in supine systolic (P , 0.01) 
and diastolic blood pressure (P , 0.005) as compared with 
baseline (145/79 + 20/9 mmHg vs 140/76 ± 16/7 mmHg).88
The available data suggest that care must be taken in 
patients with pre-existing hypertension treated with butro-
pion, due to its potential to increase blood pressure.88
A summary of the side effects of antidepressant drugs 
used in CVD is given in Table 1.
Conclusion
Twenty years ago there was a general tendency to consider 
depression a natural part of old age, especially when elderly 
patients had CVD, either cerebral or cardiac. An elderly 
patient, or one with a major stroke or myocardial infarction 
became, de facto, depressed and anxious. After 20 years, we 
need a different approach.
Depression and anxiety may be predisposing factors 
for major CVD. They are also a direct consequence, and 
their occurrence is a major predictor for a poorer recovery 
from CVD events. Correct antidepressive treatment should 
be considered a specific primary or secondary prevention 
  strategy, while bearing in mind that many studies suggest 
that antidepressants may modify platelet aggregation and 
alter the endothelium in CVD patients. Clinicians should take 
into account that many antidepressant drugs have cardiotoxic 
side effects which limit their use, and should evaluate the 
best ones to use for tailored therapy in frail elderly patients 
with CVD, multiple drug therapies, and depression.
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